1. Liang Z, Long X, Xiong Z, Wong PP, Huang S, Chen S, Zhang Y, Zhang L, Leung C, Cao J, Wu H, Yue H, Zhao Z, Tu Y, Yin B, Yang W, Wang J, Chen S, Zhang X, Tsang YW, Zhong C, Liu X, Ding L, Lu J, Si-Tou WW, Liu Y, Wang Y, Lin Y, Liang J, Ren W, Vong JS, Tong M, Tian X, Hui HX, Zhou J, Ngai S, Ni S, To KF, Braun T, Jao-Yiu Sung J, Chan SL^*, Cheng AS^*. (2026) Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-mediated fatty acid recycling. Cancer Cell, 44(6):1235-1254.e1 
2. Tu Y, Wu H, Zhong C, Liu Y, Xiong Z, Chen S, Wang J, Wong PP, Yang W, Liang Z, Lu J, Chen S, Zhang L, Feng Y, Si-Tou, WWY, Yin B, Lin Y, Liang J, Liang L, Vong JSL, Ren W, Kwong TT, Leung HHW, To KF, Ma S, Tong M, Sun H, Xia Q, Zhou J, Kerr D, La Thangue LN, Sung JJY, Chan SL^*, Cheng AS^*. (2025). Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma. Gut, 6;74(4):613-627.
3. Liu X, Liu M, Wu H, Tang W, Yang W, Chan TT, Zhang L, Chen S, Xiong Z, Liang J, Si-Tou WW, Shu T, Li JQ, Cao JQ, Zhong CP, Sun HY, Kwong TT, Leung HW, Wong J, Lai BS, To KF, Xiang TX, Sung JJY, Chan SL, Zhou JY^*, Cheng AS^*. (2024). PPP1R15A-expressing monocytic MDSCs promote immunosuppressive liver microenvironment in fibrosis-associated hepatocellular carcinoma. JHEP Reports, 4:101087.
4. Xiong Z, Chan SL, Zhou J, Vong JSL, Kwong TT, Zeng X, Wu H, Cao J, Tu Y, Feng Y, Yang W, Wong PP, Si-Tou WW, Liu X, Wang J, Tang W, Liang Z, Lu J, Li KM, Low JT, Chan MW, Leung HHW, Chan AWH, To KF, Yip KY, Lo YMD, Sung JJY^*, Cheng AS^*. (2023). Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut, 72(9):1758-1773.
5. Yang W, Feng Y, Zhou J, Cheung OK, Cao JQ, Wang J, Tang WS, Tu YL, Xu LL, Wu F, Tan Z, Sun H, Tian Y, Wong J, Lai PB, Chan SL, Chan AW, Tan P, Chen Z, Sung JJ, Yip KYL, To KF, Cheng AS^*. (2021) A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Science Translational Medicine, 13(588):eaaz6804.
6. Liu M, Zhou J, Liu X, Feng Y, Yang W, Wu F, Cheung OK, Sun H, Zeng X, Tang W, Mok MT, Wong J, Yeung PC, Lai PB, Jin H, Chen J, Chan SL, Chan AW, To KF, Chen Z, Sung JJ, Chen M, Cheng AS^*. (2020). Targeting Monocyte-intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma. Gut, 69(2):365-379.
7. Sun H, Yang W, Tian Y, Zeng X, Zhou J, Mok MTS, Tang W, Feng Y, Xu L, Chan AWH, Tong JH, Cheung YS, Lai PBS, Wang HKS, Tsang SW, Chow KL, Hu M, Liu R, Huang L, Yang B, Yang P, To KF, Sung JJY, Wong GLH^*, Wong VWS^*, Cheng AS^*. (2018). An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. Nature Communications, 9(1):5214.
8. Zhou J, Liu M, Sun H, Feng Y, Xu L, Chan AWH, Tong JH, Wong J, Chong CCN, Lai PBS, Wang HK, Tsang SW, Goodwin T, Liu R, Huang L, Chen Z, Sung JJ, Chow KL, To KF, Cheng AS^*. (2018). Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut, 67, 931-944.
9. Feng H, Yu Z, Tian Y, Lee YY, Li MS, Go MY, Cheung YS, Lai PB, Chan AM, To KF, Chan HL, Sung JJ, Cheng AS^*. (2015). A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients. Journal of Hepatology, 62(5), 1100-11
10. Yu Z, Gao YQ, Feng H, Lee YY, Li MS, Tian Y, Go MY, Yu DY, Cheung YS, Lai PB, Yu J, Wong VW, Sung JJ, Chan HL, Cheng AS^*. (2014). Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. Gut, 63(11), 1793-1804.

*(co-)corresponding author